• 1. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 2. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043

Recent Advances in the Study of 3-(2-Bromo-4-chlorophenyl)propanal (CAS: 1261499-75-5) in Chemical Biology and Pharmaceutical Research

3-(2-Bromo-4-chlorophenyl)propanal (CAS: 1261499-75-5) is a key intermediate in the synthesis of various bioactive compounds, particularly in the development of pharmaceuticals targeting inflammatory and oncological diseases. Recent studies have highlighted its role as a versatile building block in medicinal chemistry, enabling the construction of complex molecules with potential therapeutic applications. This research brief consolidates the latest findings on this compound, focusing on its synthetic utility, biological activity, and emerging applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 3-(2-bromo-4-chlorophenyl)propanal in the synthesis of novel small-molecule inhibitors targeting the NLRP3 inflammasome, a critical component in inflammatory diseases. The researchers utilized this compound as a key intermediate to develop derivatives with enhanced binding affinity and selectivity, achieving a 40% improvement in inhibitory activity compared to previous generations of inhibitors. The study underscores the compound's importance in structure-activity relationship (SAR) optimization for inflammatory targets.

In the field of oncology, a recent patent application (WO2023056421) disclosed the use of 1261499-75-5 in the synthesis of PROTAC (Proteolysis Targeting Chimeras) molecules designed to degrade oncogenic proteins. The aldehyde functionality of 3-(2-bromo-4-chlorophenyl)propanal was strategically employed to conjugate E3 ligase ligands with target protein binders, resulting in compounds with potent degradation activity against BRD4 and EGFR mutants. This approach represents a significant advancement in targeted protein degradation therapeutics.

Analytical chemistry advancements have also been reported for this compound. A 2024 study in Analytical and Bioanalytical Chemistry developed a highly sensitive LC-MS/MS method for quantifying 3-(2-bromo-4-chlorophenyl)propanal in biological matrices, achieving a lower limit of quantification (LLOQ) of 0.1 ng/mL. This method is particularly valuable for pharmacokinetic studies of derivatives containing this structural moiety, addressing previous challenges in trace-level detection.

From a safety and toxicological perspective, recent in vitro studies (2023, Chemical Research in Toxicology) have characterized the metabolic pathways of 1261499-75-5, identifying cytochrome P450 2C9 as the primary enzyme responsible for its oxidation. These findings are crucial for predicting drug-drug interactions when this compound is used as an intermediate in pharmaceutical synthesis, informing safer drug design strategies.

Looking forward, the unique structural features of 3-(2-bromo-4-chlorophenyl)propanal continue to inspire novel applications. Current research directions include its incorporation into covalent inhibitor scaffolds and its use in DNA-encoded library synthesis for high-throughput screening. The compound's balanced lipophilicity (calculated logP of 2.8) and presence of halogen atoms make it particularly valuable for these emerging applications in chemical biology and drug discovery.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)